tbuckley/cabot-search huggingface dataset:
Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta‐blocker use: a Danish nationwide cohort study
Authors: Maurizio Sessa, Annamaria Mascolo, Rikke Nørmark Mortensen, Mikkel Porsborg Andersen, Giuseppe Massimo Claudio Rosano, Annalisa Capuano, Francesco Rossi, Gunnar Gislason, Henrik Enghusen‐Poulsen, Christian Torp‐Pedersen
Journal: European Journal of Heart Failure (2017)
Erratum: Corrigendum: Induction of interleukin-8 preserves the angiogenic response in HIF-1α–deficient colon cancer cells
Authors: Y Mizukami, W-S Jo, E-M Duerr, M Gala, J Li, X Zhang, M A Zimmer, O Iliopoulos, L R Zukerberg, Y Kohgo, M P Lynch, B R Rueda, D C Chung
Journal: Nature Medicine (2006)
Altered responses to social chemosignals in autism spectrum disorder
Authors: Yaara Endevelt-Shapira, Ofer Perl, Aharon Ravia, Daniel Amir, Ami Eisen, Vered Bezalel, Liron Rozenkrantz, Eva Mishor, Liron Pinchover, Timna Soroka, Danielle Honigstein, Noam Sobel
Journal: Nature Neuroscience (2017)
The expanding spectrum of clinical phenotypes associated with <i>PSTPIP1</i> mutations: from PAPA to PAMI syndrome and beyond
Authors: H.-W. Klötgen, H. Beltraminelli, N. Yawalkar, M.E. van Gijn, D. Holzinger, L. Borradori
Journal: British Journal of Dermatology (2017)

Mutations in the PSTPIP1 gene encoding proline-serine-threonine-phosphatase interactive protein 1 were first identified in an autosomal dominant syndrome called PAPA associated with pyogenic sterile arthritis, pyoderma gangrenosum (PG) and cystic acne.1,2 . We report a patient with an autoinflammatory syndrome called PSTPIP1-associated myeloid-related proteinemia inflammatory (PAMI) syndrome.3 A 23-year-old man had a 3-year-history of skin ulcerations. This article is protected by copyright. All rights reserved.
Investigación de un brote de una afección cutánea de origen desconocido en una clínica penitenciaria de los Países Bajos en 2002
Authors: J G Breugelmans, A Bosman, A. K van der Heide, E. Y.R Roeleveld-Kuijper, D P Bruynzeel
Journal: Eurosurveillance (2003)

En octubre-noviembre de 2002, se produjo un brote de una afeccion cutanea de origen desconocido, con presencia de papulas o pustulas y picor, en mulas portadoras de drogas, en una clinica penitenciaria de los Paises Bajos. El estudio de cohorte descriptivo sugiere que el brote podria estar asociado a un lote caducado de sabanas desechables, con una tasa de ataque global del 30% en la poblacion del estudio (n=118). No se observaron mas casos desde la sustitucion del lote caducado.
Renal-Cell Carcinoma
Authors: Robert J. Motzer, Neil H. Bander, David M. Nanus
Journal: New England Journal of Medicine (1996)

Renal-cell carcinoma is characterized by a lack of early-warning signs (which results in a high proportion of patients with metastases), diverse clinical manifestations, and resistance to radiotherapy and chemotherapy, and there is a potential role for immunomodulation in the inhibition of tumor growth. In this review we discuss recent developments in epidemiology, histologic classification, tumor biology, methods of diagnosis and staging, surgical techniques, and immunotherapy for patients with metastatic disease.EpidemiologyRenal-cell carcinoma accounts for 2 percent of all cancers.1 Its incidence varies among countries by a factor of 20 among men and by a factor of 10 among women, . . .
Campaigners vow to fight on after report finds no link between hormone test and birth defects
Authors: Anne Gulland
Journal: BMJ (2017)

Campaigners have called for a judicial review after a UK government report found that hormone based pregnancy tests (HPTs) given to women in the 1960s and 1970s did not cause birth defects.

An expert working group of the Commission on Human Medicines, an advisory non-departmental public body sponsored by the Department of Health for England, found that after “an extensive review” of the evidence on the tests there was no “causal association between the use of HPTs . . . and birth defects or miscarriage.”1

Marie Lyon, chair of the Association for Children Damaged by Hormone Pregnancy Tests, …
The efficacy of eribulin mesylate with trastuzumab for locally advanced or metastatic HER2-positive breast cancer treated with prior pertuzumab and/or T-DM1: Results from a phase II, single arm, multicenter study (N-SOG 10 study)
Authors: M. Fujii, N. Tsunoda, M. Hattori, T. Murata, K. Akahane, K. Kamei, Y. Goto, T. Amemiya, K. Nishimae, T. Kubota, Y. Ito, Y. Kurumiya, M. Yoshihara, K. Nakanishi, T. Kikumori, M. Ando, M. Nagino
Journal: Annals of Oncology (2017)
La notificación obligatoria de los laboratorios en Alemania : una encuesta sobre actitudes, prácticas y necesidades
Authors: A P Zucs, J Benzler, G Krause
Journal: Eurosurveillance (2005)

En 2000, la nueva ley alemana sobre el control de enfermedades infecciosas sustituyo la notificacion agregada de casos por la declaracion individual. Este proceso fue facilitado por la introduccion simultanea de un sistema de transferencia electronica de datos en el Sistema de salud publica. Los laboratorios notificadores no habian sido conectados electronicamente a esa red. Se llevo a cabo una encuesta en 2003, por medio de un cuestionario mandado por correo a 537 laboratorios alemanes de microbiologia medica, con el objetivo de conocer sus habitos de declaracion, sus preferencias en cuanto a formatos de declaracion electronica y equipos de software. Cerca del 90% de los que respondieron indicaron un plazo de declaracion no superior a 24 horas, y el 45% seguian completando manualmente formularios de declaracion. El 74% de los laboratorios se mostraron favorables a la notificacion electronica. El 33% de ellos no usan ningun software microbiologico especifico y el resto (67%) mencionaron hasta 62 productos diferentes. En este sentido, podrian ser utiles proyectos piloto en colaboracion con fabricantes de software seleccionados, para implantar un formato electronico estandardizado de declaracion de las enfermedades infecciosas en Alemania.
Weight management and physical activity throughout the cancer care continuum
Authors: Wendy Demark‐Wahnefried, Kathryn H. Schmitz, Catherine M. Alfano, Jennifer R. Bail, Pamela J. Goodwin, Cynthia A. Thomson, Don W. Bradley, Kerry S. Courneya, Christie A. Befort, Crystal S. Denlinger, Jennifer A. Ligibel, William H. Dietz, Melinda R. Stolley, Melinda L. Irwin, Marcas M. Bamman, Caroline M. Apovian, Bernardine M. Pinto, Kathleen Y. Wolin, Rachel M. Ballard, Andrew J. Dannenberg, Elizabeth G. Eakin, Matt M. Longjohn, Susan D. Raffa, Lucile L. Adams‐Campbell, Joanne S. Buzaglo, Sharyl J. Nass, Greta M. Massetti, Erin P. Balogh, Elizabeth S. Kraft, Anand K. Parekh, Darshak M. Sanghavi, G. Stephen Morris, Karen Basen‐Engquist
Journal: CA A Cancer Journal for Clinicians (2017)

Abstract Mounting evidence suggests that weight management and physical activity (PA) improve overall health and well being, and reduce the risk of morbidity and mortality among cancer survivors. Although many opportunities exist to include weight management and PA in routine cancer care, several barriers remain. This review summarizes key topics addressed in a recent National Academies of Science, Engineering, and Medicine workshop entitled, “Incorporating Weight Management and Physical Activity Throughout the Cancer Care Continuum.” Discussions related to body weight and PA among cancer survivors included: 1) current knowledge and gaps related to health outcomes; 2) effective intervention approaches; 3) addressing the needs of diverse populations of cancer survivors; 4) opportunities and challenges of workforce, care coordination, and technologies for program implementation; 5) models of care; and 6) program coverage. While more discoveries are still needed for the provision of optimal weight‐management and PA programs for cancer survivors, obesity and inactivity currently jeopardize their overall health and quality of life. Actionable future directions are presented for research; practice and policy changes required to assure the availability of effective, affordable, and feasible weight management; and PA services for all cancer survivors as a part of their routine cancer care. CA Cancer J Clin 2018;68:64‐89 . © 2017 American Cancer Society .
Health-related quality of life of postmenopausal women with hormone receptor–positive, HER2- advanced breast cancer treated with ribociclib + letrozole: Results from MONALEESA-2.
Authors: Sunil Verma, Joyce O'Shaughnessy, Howard A. Burris, Mario Campone, Emilio Alba, David Chandiwana, Stephanie Manson, Santosh C. Sutradhar, Mauricio Monaco, Wolfgang Janni
Journal: Journal of Clinical Oncology (2017)

133 Background: In the MONALEESA-2 trial, ribociclib + letrozole significantly improved progression-free survival and showed higher overall response rates vs placebo + letrozole in hormone receptor–positive, HER2– advanced breast cancer. Here, we present key patient-reported outcomes including health-related quality of life (HRQoL). Methods: Six hundred sixty-eight patients were randomized (n = 334 for each treatment group). Patient-reported outcomes were evaluated during treatment and at progression using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and QLQ-BR23. Changes from baseline in all subscales were analyzed using a linear mixed-effects model, and time to 10% deterioration was compared between treatment arms using the stratified log-rank test. Results: Questionnaire adherence rates were high ( &gt; 90%). During treatment, HRQoL (global health status/QoL score) was maintained and similar in both treatment arms. At progression/end of treatment, HRQoL worsened numerically in both arms. Time to definitive 10% deterioration of HRQoL was similar between treatment groups, slightly favoring the ribociclib + letrozole arm (hazard ratio, 0.944; 95% confidence interval, 0.720–1.237). No statistically or clinically relevant differences were observed for key symptoms using EORTC QLQ-C30 including fatigue, nausea, and vomiting. There was clinically relevant improvement ( &gt; 5 points) in pain from baseline to post baseline (through cycle 15) in the ribociclib + letrozole arm, but only mild improvement (≤5 points) in the placebo + letrozole arm. Conclusions: Ribociclib + letrozole maintained HRQoL, and a numerical trend favoring ribociclib + letrozole was observed for pain reduction and delay. Clinical trial information: NCT01958021.
Hepatitis C virus infection in vulnerable populations: a seroprevalence study of homeless, people who inject drugs and prisoners in London, UK
Authors: Dewi Nur Aisyah, Laura Shallcross, Andrew Hayward, Robert W Aldridge, Sara Hemming, Susan Yates, Gloria Ferenando, Lucia Possas, Elizabeth Garber, John M Watson, Anna Maria Geretti, Timothy D McHugh, Marc Lipman, Alistair Story
Journal: The Lancet (2017)
Hepatitis B Vaccination, Screening, and Linkage to Care: Best Practice Advice From the American College of Physicians and the Centers for Disease Control and Prevention
Authors: Winston E. Abara, Amir Qaseem, Sarah Schillie, Brian J. McMahon, Aaron M. Harris
Journal: Annals of Internal Medicine (2017)

Background: Vaccination, screening, and linkage to care can reduce the burden of chronic hepatitis B virus (HBV) infection. However, recommendations vary among organizations, and their implementation has been suboptimal. The American College of Physicians' High Value Care Task Force and the Centers for Disease Control and Prevention developed this article to present best practice statements for hepatitis B vaccination, screening, and linkage to care. Methods: A narrative literature review of clinical guidelines, systematic reviews, randomized trials, and intervention studies on hepatitis B vaccination, screening, and linkage to care published between January 2005 and June 2017 was conducted. Best Practice Advice 1: Clinicians should vaccinate against hepatitis B virus (HBV) in all unvaccinated adults (including pregnant women) at risk for infection due to sexual, percutaneous, or mucosal exposure; health care and public safety workers at risk for blood exposure; adults with chronic liver disease, end-stage renal disease (including hemodialysis patients), or HIV infection; travelers to HBV-endemic regions; and adults seeking protection from HBV infection. Best Practice Advice 2: Clinicians should screen (hepatitis B surface antigen, antibody to hepatitis B core antigen, and antibody to hepatitis B surface antigen) for HBV in high-risk persons, including persons born in countries with 2% or higher HBV prevalence, men who have sex with men, persons who inject drugs, HIV-positive persons, household and sexual contacts of HBV-infected persons, persons requiring immunosuppressive therapy, persons with end-stage renal disease (including hemodialysis patients), blood and tissue donors, persons infected with hepatitis C virus, persons with elevated alanine aminotransferase levels (≥19 IU/L for women and ≥30 IU/L for men), incarcerated persons, pregnant women, and infants born to HBV-infected mothers. Best Practice Advice 3: Clinicians should provide or refer all patients identified with HBV (HBsAg-positive) for posttest counseling and hepatitis B–directed care.
Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: More details, more significance
Authors: Youliang Pei, Xiao‐ping Chen, Wanguang Zhang
Journal: Hepatology (2017)

Potential conflict of interest: Nothing to report. TO THE EDITOR: We read with great interest the recent article by Kokudo et al.1 in Hepatology (August 2017), which explored the prognosis of liver resection for patients with hepatocellular carcinoma (HCC) and hepatic vein tumor thrombus (HVTT) using a Japanese nation‐wide survey data. They reported that liver resection in patients with HCC and HVTT achieved a good prognosis, especially in those without portal vein tumor thrombus. However, we noticed that the recurrence‐free survival time in one subgroup was significantly shorter than that in another subgroup. This relatively poor outcome may be attributed, in part, to the subclassification of HVTT or the application of specific surgical techniques. Herein, we would like to raise the following concerns. First, one key factor affecting prognosis is the subclassification of HVTT. The researchers just categorized the HVTT into the peripheral HVTT (pHVTT) and the major HVTT (mHVTT) according to the radiological finding, but the definition of “peripheral” and “major” is quite robust and abstract so that it is difficult to imagine which one belongs to the pHVTT or the mHVTT. In spite of the good prognosis of liver resection for patients with HCC and HVTT in this nation‐wide survey, patients with mHVTT had remarkably shorter recurrence‐free survival time (0.88 vs. 2.36 years) and a greater proportion of distant metastasis (21.5% vs. 11.0%) than those with pHVTT had, as shown in Table 3 of this study. The ambiguous subclassification of HVTT usually makes it difficult for surgeons to select the optimal candidates for operation, so that we believe a clear subclassification of HVTT is necessary to make in the present study. Second, another key factor affecting the prognosis is the application of specialized surgical procedures in patients with HCC and HVTT. Previous studies had stated that the application of anatomical resection and anterior approach could decrease the probability of intrahepatic recurrence and distant metastasis.2 However, crucial information about the surgical techniques were not described in the present study. Therefore, we are very interested in whether the researchers can verify our hypothesis in the present study: whether the application of anatomical resection and anterior approach procedure can preclude the shedding of HVTT during operation and improve the prognosis, particularly reducing the distant metastasis. We believe that these further explorations can be made through mining of the existing data. If this hypothesis were proved to be true in this nation‐wide study, it would undoubtedly be more meaningful and practical.
Abstract 20931: Therapeutic Hypothermia in In Hospital Cardiac Arrest
Authors: Shilpkumar Arora, Varun Kumar, Byomesh Tripathi, Sopan Lahewala, Vishwa Kundoor, Mihir Dave, Smit Patel, Subir Bhatia, Harshil Shah, Umesh Gidwani, Radha Gopalan
Journal: Circulation (2017)

Introduction: Role of therapeutic hypothermia in out of hospital cardiac arrest is well studied but data is sparse for in-hospital cardiac arrest (IHCA). Methods: Nationwide Inpatient Sample (NIS) database from 2011-2014 was utilized to identify ICHA using the ICD-9-CM procedural codes 99.60(CPR) and 99.63(closed cardiac massage) in any procedural fields. Therapeutic hypothermia was identified by 99.81 in any procedural field. Patient with age&lt;18 years and missing information on age, gender and mortality was removed. Primary outcome was hospitalization survival. We used Greedy’s algorithm for propensity score match (1:20) to adjust for extensive list of clinically important confounders. We used simple logistic regression to generate odds ratio on matched cohort. Results: 86,593 patients (Age&gt;65 years: 58.48%, female: 44.12%) with In hospital cardiac arrest was identified,of which 1777 (2.05 %) received therapeutic hypothermia. Overall survival was 30%- with or without hypothermia. After propensity score matching (1:20) we identified 1537 matched pairs (32,277 patients) without any statically significant difference in baseline characteristics between two groups. C- index for the model was 0.714. Worse survival was observed in patients with hypothermia in matched cohort [Survival: (31.82% without hypothermia vs. 28.1% with hypothermia with p-value- 0.002) (OR:0.84, 95% CI:0.75-0.94, p-0.002)]. About a quarter of in-hospital cardiac arrest were Vfib/Vtach arrest and Subgroup propensity score match analysis in Vfib/Vtach arrest showed better survival without hypothermia, similar results were observed in PEA/asystole cardiac arrest. Conclusion: Worst survival was observed with hypothermia in hospital cardiac arrest patients. Risk of hypothermia complications outweighs the benefit of preserving brain in patients who received almost immediate resuscitation. Future clinical trials and prospective studies will be needed to concur our results.
Correction to: Potentially modifiable factors contributing to outcome from acute respiratory distress syndrome: the LUNG SAFE study
Authors: John G. Laffey, Giacomo Bellani, Tài Pham, Eddy Fan, Fabiana Madotto, Ednan K. Bajwa, Laurent Brochard, Kevin Clarkson, Andres Esteban, Luciano Gattinoni, Frank van Haren, Leo M. Heunks, Kiyoyasu Kurahashi, Jon Henrik Laake, Anders Larsson, Daniel F. McAuley, Lia McNamee, Nicolas Nin, Haibo Qiu, Marco Ranieri, Gordon D. Rubenfeld, B. Taylor Thompson, Hermann Wrigge, Arthur S. Slutsky, Antonio Pesenti
Journal: Intensive Care Medicine (2017)
CT-P10 versus reference rituximab in combination with CVP in advanced-stage follicular lymphoma: Phase 3, double-blind, randomized trial
Authors: W.S. Kim, B. Coiffier, C. Buske, M. Ogura, L. Kwak, W. Jurczak, J.M. Sancho, E. Zhavrid, J.S. Kim, J-Á Hernández-Rivas, A. Prokharau, M. Vasilica, R. Nagarkar, S.J. Lee, S.Y. Lee, Y.J. Bae
Journal: Annals of Oncology (2017)
Art enhances meaning by stimulating integrative complexity and aesthetic interest
Authors: Henrik Hagtvedt, Kathleen D Vohs
Journal: Behavioral and Brain Sciences (2017)

Abstract Menninghaus et al. portrayed meaning in art as a vehicle for transforming negative emotions into pleasure. Although it is intuitively appealing that meaningful experiences should feel good, meaningfulness does not necessarily entail pleasure or positive emotions. Whereas easily comprehended art may elicit pleasure, meaningfulness is more closely tied to challenge and interest than to pleasure.
Standardization of inpatient CPR status discussions and documentation within the Division of Hematology and Oncology at UPMC Shadyside Hospital.
Authors: Christine Ann Garcia, Mamta Bhatnagar, Rachel Rodenbach, Melissa Winfield, Abigail Graham-Pardus, Christopher Minnier, Sharon Hanchett, Jamie Kriner, Emily Baird, Janet Leahy, Edward Chu, Stanley M. Marks, Josh Levenson
Journal: Journal of Clinical Oncology (2017)

147 Background: Medical professionals are trained to provide life-sustaining and cardiac resuscitation measures for admitted hospital patients. However, not all patients desire such aggressive measures. Lack of discussion and/or documentation about resuscitation preferences has led to care incongruous with patient’s wishes as previously documented or reported to providers or family members. In December 2016, 49% of adult patients admitted to the inpatient oncology service at UPMC Shadyside had a code status discussion documented prior to discharge. The aim of this project is to improve the quality and rates of CPR status conversations. Methods: A workgroup was formed in January 2017 among key stakeholders representing oncology physicians and fellows, palliative care faculty, oncology nursing, advance practice providers (APPs), and internal medicine house staff. A quality improvement (QI) proposal was developed and approved by the UPMC Quality Improvement Committee in February 2017. All oncology faculty, fellows, housestaff, and APPs were reminded weekly to complete CPR status conversations and documentation. APPs were formally trained by palliative care specialists to discuss and document CPR/code status with all admitted patients. Hospital leadership received a monthly update of CPR status documentation rates. Results: Since project implementation, CPR status assessment rates have improved from 49% to 80% as of June 2017, and an additional 714 patients had a CPR status discussed and documented compared to June 2016. Formal system-wide expectations are being developed by the CPR assessment workgroup that all admitted patients should have CPR/Code status discussions and documentation upon admission. Conclusions: Standardization of CPR status assessment with formal training of clinicians and APPs has resulted in a significant increase in the number of CPR status assessments on the inpatient setting. A formal CPR status assessment expectations document is in the process of being developed among the workgroup. Formal trainings by palliative care specialists for APPs are ongoing. Future trainings are planned for physicians, housestaff and fellows.
Adaptive Immune Receptor Repertoire Community recommendations for sharing immune-repertoire sequencing data
Authors: Florian Rubelt, Christian E Busse, Syed Ahmad Chan Bukhari, Jean-Philippe Bürckert, Encarnita Mariotti-Ferrandiz, Lindsay G Cowell, Corey T Watson, Nishanth Marthandan, William J Faison, Uri Hershberg, Uri Laserson, Brian D Corrie, Mark M Davis, Bjoern Peters, Marie-Paule Lefranc, Jamie K Scott, Felix Breden, Eline T Luning Prak, Steven H Kleinstein
Journal: Nature Immunology (2017)
Le botulisme en Norvège
Authors: M Kuusi, V Hasseltvedt, P Aavitsland
Journal: Eurosurveillance (1999)

Le botulisme est une maladie paralysante grave provoquee par une toxine elaboree par Clostridium botulinum, un germe anaerobie produisant des spores. En Norvege, les medecins doivent declarer immediatement au National Institute of Public Health (NIPH) les cas de botulisme, par telephone et par courrier avec le formulaire de declaration standard. Le nom du patient, son âge, sa date de naissance, son numero d’identification, son adresse et la source suspectee de l’infection y sont precises. Depuis 1975, toutes les donnees de surveillance sont stockees dans la base de donnees du NIPH. En Norvege, le botulisme d’origine alimentaire est rare. Le botulisme du nourrisson et le botulisme par blessure ont ete rapportes pour la premiere fois en 1997 (1). L’augmentation recente du nombre de cas de botulisme en Norvege (figure 1) a mis en lumiere l’importance de rester vigilant non seulement pour ameliorer la detection des cas, mais aussi pour assurer des mesures preventives.
Pathogenic TH17 inflammation is sustained in the lungs by conventional dendritic cells and Toll-like receptor 4 signaling
Authors: Karim H. Shalaby, Miranda R. Lyons-Cohen, Gregory S. Whitehead, Seddon Y. Thomas, Immo Prinz, Hideki Nakano, Donald N. Cook
Journal: Journal of Allergy and Clinical Immunology (2017)